The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France

Clinical Therapeutics

Volumn 28, Issue 10, 2006, Pages 1686-1694

  Cramer, Joyce A ^a   Lynch, Niall O ^b   Gaudin, Anne Francoise ^c   Walker, Mel ^d   Cowell, Warren ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (France)

^d ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

bisphosphonate; compliance; persistence; United Kingdom, France; United States

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID;

AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; FRANCE; GENERAL PRACTITIONER; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MEDICAL RECORD; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; RETROSPECTIVE STUDY; UNITED KINGDOM; UNITED STATES;

COHORT STUDIES; DIPHOSPHONATES; FEMALE; FRANCE; GREAT BRITAIN; HUMANS; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; UNITED STATES;

EID: 33751519723     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.10.013     Document Type: Article

References (45)

1. Tsugeno H., Tsugeno H., Fujita T., et al. Vertebral fracture and cortical bone changes in corticosteroid-induced osteoporosis. Osteoporos Int 13 (2002) 650-656
2. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843 (1994), WHO, Geneva, Switzerland
3. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359 (2002) 1929-1936
4. Ray N.F., Chan J.K., Thamer M., and Melton III L.J. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Fou ndation. J Bone Miner Res 12 (1997) 24-35
5. National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation (2002), National Osteoporosis Foundation, Washington, DC
6. Kanis J.A., and Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16 (2005) 229-238
7. Benner J.S., Glynn R.J., Mogun H., et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461
8. Christensen D.B., Williams B., Goldberg H.I., et al. Assessing compliance to antihypertensive medications usingcomputerbased pharmacy records. Med Care 35 (1997) 1164-1170
9. Miller N.H. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102 (1997) 43-49
10. Black D.M., Cummings S.R., Karpf D.B., et al., Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
11. Harris S.T., Watts N.B., Genant H.K., et al., Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 282 (1999) 1344-1352
12. Delmas P.D., Ensrud K.E., Adachi J.D., et al., Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87 (2002) 3609-3617
13. Chesnut III C.H., Skag A., Christiansen C., et al., Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral iban dronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
14. Yood R.A., Emani S., Reed J.I., et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14 (2003) 965-968
15. McCombs J.S., Thiebaud P., McLaughlin-Miley C., and Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
16. Papaioannou A., Ioannidis G., Adachi J.D., et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14 (2003) 808-813
17. Segal E., Tamir A., and Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 5 (2003) 859-862
18. Caro J.J., Ishak K.J., Huybrechts K.F., et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15 (2004) 1003-1008
19. Abstract M406. Lombas C., Hakim C., and Zanchetta J.R. Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 15 Suppl 1 (2001) S529
20. Recker R.R., Gallagher R., and MacCosbe P.E. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80 (2005) 856-861
21. Cramer J.A., Amonkar M.M., Hebborn A., and Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21 (2005) 1453-1460
22. Seatte, Wash. Sebaldt R.J., Shane L.G., Pham B.Z., et al. Impact of noncompliance and non-persistence with daily-regimen bisphosphonates on longer term effectiveness outcomes in patients with osteoporosis. Poster presented at: Annual Meeting of the American Society for Bone Mineral Research. Poster M423 (October 1-5, 2004)
23. Tosteson A.N., Grove M.R., Hammond C.S., et al. Early discontinuation of treatment for osteoporosis. Am J Med 115 (2003) 209-216
24. Hamilton B., McCoy K., and Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14 (2003) 259-262
25. The Adherence Gap: Why osteoporosis patients don't continue with treatment. A European report highlighting the gap between the beliefs of people with osteoporosis and the perceptions of their physicians. International Osteoporosis Foundation (2005)
26. Simon J.A., Lewiecki E.M., Smith M.E., et al. Patient preference for once weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, openlabel, crossover study. Clin Ther 24 (2002) 1871-1886
27. Kendler D., Kung A.W., Fuleihan G.-H., et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48 (2004) 243-251
28. Catalan V.S., and LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 3 (2000) 417-426
29. Breekveldt-Postma N.S., and Herings R.M. Persistence with antihypertensives related to formulation: The case of nifedipine. Ann Pharmacother 39 (2005) 237-242
30. Cramer J.A. Partial medication compliance: The enigima in poor medical outcomes. Am J Manag Care 1 (1995) 167-176
31. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 (2001) 1296-1310
32. Solomon D.H., Avorn J., Katz J.N., et al. Compliance with osteoporosis medications. Arch Intern Med 165 (2005) 2414-2419
33. Dunbarjacob J., Erlen J.A., Schlenk E.A., et al. Adherence in chronic disease. Annu Rev Nurs Res 18 (2000) 48-90
34. Simons L.A., Levis G., and Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 164 (1996) 208-211
35. Ettinger B., Pressman A.R., Schein J., et al. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, non-compliance with patient instructions and discontinuation. J Manag Care Pharm 4 (1998) 488-492
36. Abstract P7.10. Boccuzzi S.J., Folz S.H., Omar M.A., et al. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int 16 Suppl 4 (2005) S35-S36
37. (Suppl). Ettinger M.P., Gallagher R., and Amonkar M. Medication persistence is improved with less frequent dosing of bisphosphonates but remains inadequate. Abstract 1325. Arthritis Rheum 15 (2004) S513
38. Eastell R., Garnero P., Vrijens B., et al. Influence of patient compliance with risedronate therapy on bone turn over marker and bone mineral density response: The IMPACT study. Calcif Tissue Int 72 (2003) P-297
39. Abstract P110. Finigan J., Bainbridge P.R., and Eastell R. Adherence to osteoporosis therapies. Osteoporos Int 12 (2001) S48-S49
40. Siris E.S., Harris S.T., Rosen C.J., et al. Adherence to bisphosphonate ther apy and fracture rates in osteoporotic women: Relationship to vertebral and nonvetebral fractures from 2 US claims databases. Mayo Clin Proc 81 (2006) 1013-1022
41. Cramer J., Rosenheck R., Kirk G., et al., VA Naltrexone Study Group 425. Medication compliance feedback and monitoring in a clinical trial: Predictors and outcomes. Value Health 6 (2003) 566-573
42. (Suppl). Thompson P., Cooper C., and Carr A. Factors influencing adherence to bisphosphonates for osteoporosis. Arthritis Rheum 52 (2005) S257-S258
43. Emkey R., Koltun W., Beusterien K., et al. Patient preference for once monthly ibandronate versus onceweekly alendronate in a randomized, open label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21 (2005) 1895-1903
44. [published correction appears in Lancet. 1997;349:1180]. Haynes R.B., McKibbon K.A., and Kanani R. Systematic review of randomised trials of interventions to assist pa tients to follow prescriptions for medications. Lancet 348 (1996) 383-386
45. Motheral B.R., and Fairman K.A. The use of claims databases for outcomes research: Rationale, challenges, and strategies. Clin Ther 19 (1997) 346-366